top stories

Go­ing 0-for-4 on a big PhI­II pro­gram, No­var­tis scraps their top asth­ma prospect and sig­nal big trou­ble for a lit­tle biotech

3 minutes ago
R&D

Ju­ry finds Gilead li­able for $585M and big roy­al­ties in Kite CAR-T patent case

2 days ago
Cell/Gene Tx

Amarin wins a block­buster ap­proval from the FDA. Now every­one can shift fo­cus to the patent

2 days ago
Pharma
Regulatory

Latest

Most read

Sanofi CEO Hud­son lays out new R&D fo­cus — chop­ping di­a­betes, car­dio and slash­ing $2B-plus costs in sur­gi­cal ...

6 days ago
R&D

FDA ex­pert pan­el unan­i­mous­ly rec­om­mends ap­proval for Hori­zon Ther­a­peu­tics eye drug

2 days ago
Regulatory

Bio­phar­ma has aban­doned an­tibi­ot­ic de­vel­op­ment. Here’s why we did, too.

2 days ago
Biotech Voices

Shehnaaz Suli­man dives back in­to Alzheimer's at Alec­tor; Pyx­is re­cruits Spring­Works founder Lara Sul­li­van as CEO

2 days ago
Peer Review
see latest stream
People

Bris­tol-My­er­s' strat­e­gy, BD chief Paul Bion­di ex­it­ed the com­pa­ny — just ahead of the $74B Cel­gene deal close

3 days ago

South Ko­rea jails 3 Sam­sung ex­ecs for de­stroy­ing ev­i­dence in Bi­o­Log­ics probe

5 days ago

One of Wall Street’s most high-pro­file hedge funds push­es Alex­ion's CEO to the auc­tion block — and he's not ...

Last week
Startups

Parkin­son's trans­plants emerge as stem cell pi­o­neer Jeanne Lor­ing joins R&D race

4 days ago

Cel­lar­i­ty, Flag­ship's $50M bet on net­work bi­ol­o­gy, mar­ries ma­chine learn­ing and sin­gle-cell tech for drug dis­cov­ery

5 days ago

Per­cep­tive teams up with Chris Garabe­di­an to open up a new, $210M biotech fund fo­cused on A rounds

5 days ago
Deals

Bat­tered, cash hun­gry In­tec feels the burn of No­var­tis re­jec­tion

4 days ago

Ab­b­Vie, Scripps ex­pand part­ner­ship, for­ti­fy fo­cus on can­cer drugs

5 days ago

In a play-by-play of the $9.7B Med­Co buy­out, No­var­tis ad­mits it over­paid while of­fer­ing a huge wind­fall to ex­ecs

6 days ago
IPOs

Al­pham­ab On­col­o­gy rounds out HKEX's sec­ond biotech IPO year with $230M raise and high lo­cal in­ter­est

3 days ago

With mo­men­tum from FDA OK, SK Bio­phar­ma to breath new life in­to Ko­re­an biotech with $850M IPO — re­port

3 weeks ago

Tot Bio­pharm com­pletes HKEX list­ing, rais­ing $63M in mod­est de­but

Last month

All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.

SUBSCRIBE NOW
Subscribe to Endpoints News

Premium storiesSee all

Paul Biondi's track record at Bris­tol-My­ers cov­ered bil­lions in deals of every shape and size. Here's the com­plete ...

2 days ago
R&D

The big drug hunters: No­var­tis’ $28B-plus deal spree makes Vas Narasimhan one of the top deal­mak­ers of our time

3 weeks ago

Stephen Hahn gets through Sen­ate’s soft­ball job in­ter­view — but most­ly plays dodge­ball on the is­sues fac­ing the ...

4 weeks ago
Bioregnum

Eliz­a­beth War­ren pro­pos­es us­ing com­pul­so­ry li­cens­ing, an­titrust ac­tions to break bio­phar­ma’s con­trol of drug ...

4 weeks ago
Bioregnum
Pharma

Don't missSee all

What's next for Sarep­ta? A third DMD ap­proval, an­a­lysts pre­dict

2 days ago
Regulatory

Sarep­ta was stunned by the re­jec­tion of Vyondys 53. Now it's stun­ning every­one with a sur­prise ac­cel­er­at­ed ap­proval

3 days ago
R&D
Regulatory

Kite Phar­ma's ex-CEO con­tra­dicts founder as CAR-T patent tri­al heats up, with con­flict­ing val­u­a­tions

3 days ago
Cell/Gene Tx

On the heels of promis­ing MCL da­ta, Kite hus­tles its 2nd CAR-T to the FDA as the next big race in the field draws to ...

3 days ago
R&D

Endpoints Standouts

Spe­cial re­port: Twen­ty ex­tra­or­di­nary women in bio­phar­ma R&D who worked their way to the top

Last month
People
R&D

Un­lock the full End­points ex­pe­ri­ence for your com­pa­ny — and sup­port our mis­sion of in­de­pen­dent bio­phar­ma re­port­ing

Last week
Publisher's note

[Video] Cel­e­brat­ing tri­al fail­ures, chang­ing the cul­ture and al­ly­ing with Cal­i­for­nia dream­ers: R&D chief Hal Bar­ron ...

2 months ago

[Video] Putting the AI in R&D — with Badhri Srini­vasan, Tony Wood, Rosana Kapeller, Hugo Ceule­mans, Saurabh Sa­ha ...

3 months ago
AI

Peer review See all

Dec
6

Ex-Cel­gene ex­ec Ter­rie Cur­ran puts her Phath­om team in place; Car­away taps Mar­tin Williams as CEO

Nov
27

Biotech vet Paul Bren­nan takes helm at re­gen­er­a­tive med biotech; Ax­cel­la names CFO

Nov
22

Cel­gene R&D vet jumps to biotech: 'It’s about short­en­ing the cy­cle'; No­var­tis ex­o­dus con­tin­ues as William Chou takes the helm at Aru­vant

Nov
15

Ab­bott Lab­o­ra­to­ries CEO Miles White pass­es ba­ton down to suc­ces­sor; Lon­za CEO Marc Funk hits the ex­it

Nov
8

An­ces­tryD­NA chief takes on liq­uid biop­sy chal­lenge; Thomas Lynch chairs for­mer col­league's can­cer start­up

R&D channel feed

4 days ago

What does $6.9B buy these days in on­col­o­gy R&D? As­traZeneca has a land­mark an­swer

Giv­en the way the FDA has been whisk­ing through new drug ap­provals months ahead of their PDU­FA date, As­traZeneca and their part­ners Dai­ichi Sankyo may not have to wait un­til Q2 of next ...

READ MORE

PhII fail­ure in rare neu­rode­gen­er­a­tive dis­ease? No mat­ter, Bio­gen will mo­tor on in Alzheimer's

2 days ago

Roche's triplet in­volv­ing Tecen­triq clears the PFS bar for melanoma when added to BRAF/MEK com­bo

2 days ago
Pharma
latest in R&D

KRAS analy­sis vaults Mer­ck­'s flag­ship Keytru­da back in­to the spot­light

3 days ago

Cor­re­vio is putting it­self up on the auc­tion block af­ter FDA re­view pan­el points to an­oth­er re­jec­tion

3 days ago

In a key step for psy­che­del­ic re­search, mag­ic mush­room com­pound clears first clin­i­cal safe­ty hur­dle

3 days ago

For sale: Long-act­ing PhI­II GLP-1 di­a­betes drug that’s way be­hind ri­vals, now spurned by Sanofi

3 days ago

FDA in-house re­view spot­lights an is­sue with one of Hori­zon's end­points but notes ef­fi­ca­cy for lead drug

4 days ago
see latest stories

Pharma channel feed

2 days ago

A USP­TO le­gal ad­vis­er is off con­tro­ver­sial Gilead HIV case af­ter ac­tivists al­lege tweets show bias

Last week, a top le­gal ad­vis­er in the US Patent and Trade­mark Of­fice work­ing on the high-pro­file Gilead HIV PrEP case tweet­ed at Sen Bernie Sanders (I-VT) "What proof????" and then at ...

READ MORE

House pass­es Pelosi drug pric­ing bill on par­ty-line vote

3 days ago

As­traZeneca joins Mer­ck, Bris­tol-My­ers in Chi­na's check­point race as reg­u­la­tors OK first PD-L1

3 days ago
China
latest in Pharma

Am­gen puts its foot down in shiny new South San Fran­cis­co hub as it re­or­ga­nizes R&D ops

5 days ago
R&D

Re­pub­li­cans un­veil a drug price bill to ri­val the De­moc­rats — promis­ing low­er prices and more cures

5 days ago

US biosim­i­lar launch­es about to turn a cor­ner

5 days ago

While No­var­tis com­bats gener­ic on­slaught in the courts, FDA ap­proves first Gilenya copy­cats

Last week
Regulatory

In a win for in­dus­try, Trump ad­min­is­tra­tion is­sues scathing re­view of Pelosi drug pric­ing bill

Last week
see latest stories